2013
Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas
Ivanov SV, Panaccione A, Nonaka D, Prasad ML, Boyd KL, Brown B, Guo Y, Sewell A, Yarbrough WG. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. British Journal Of Cancer 2013, 109: 444-451. PMID: 23799842, PMCID: PMC3721393, DOI: 10.1038/bjc.2013.326.Peer-Reviewed Original ResearchConceptsBasal-like breast carcinomasAdenoid cystic carcinomaGene signatureBreast cancerSox10 expressionDiagnostic markerBasal-like carcinomasExpression of ERPotential molecular markersSensitive diagnostic markerPotential therapeutic targetBasal cell markersNovel diagnostic markerSalivary adenoid cystic carcinomaMyoepithelial featuresBreast subtypesAdenoid cysticBreast carcinomaCystic carcinomaImmunohistochemical stainingMolecular subtypesHistological similaritiesTherapeutic targetTranscriptional program characteristicDiagnostic significance
2009
IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype
Walter O, Prasad M, Lu S, Quinlan R, Edmiston K, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Human Pathology 2009, 40: 1528-1533. PMID: 19695680, DOI: 10.1016/j.humpath.2009.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedNeoplasm ProteinsPhenotypeReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesRNA-Binding ProteinsConceptsHuman epidermal growth factor receptor 2Invasive mammary carcinomaInvasive ductal carcinomaIMP3 expressionNovel biomarkersDuctal carcinomaProgesterone receptorMammary carcinomaBreast cancerEstrogen receptorAggressive phenotypeEpidermal growth factor receptor 2Triple-negative breast cancerDisease-free survivalBiologic prognostic factorsGrowth factor receptor 2Lymph node metastasisInsulin-like growth factor II mRNABasal-like carcinomasGrowth factor II mRNABasal epithelial markersNegative breast cancerBreast cancer casesFactor receptor 2Mouse monoclonal antibody
2000
Are microinvasion and micrometastasis in breast cancer mountains or molehills?
Hoda S, Chiu A, Prasad M, Giri D, Hoda R. Are microinvasion and micrometastasis in breast cancer mountains or molehills? The American Journal Of Surgery 2000, 180: 305-308. PMID: 11113441, DOI: 10.1016/s0002-9610(00)00464-5.Commentaries, Editorials and LettersMeSH KeywordsAxillaBreastBreast NeoplasmsFemaleHumansLymph NodesLymphatic MetastasisNeoplasm InvasivenessConceptsMicrometastatic carcinomaWidespread mammographic screeningSentinel lymph nodesDepartment of PathologyRate of diagnosisComputerized literature searchRate of detectionLymph nodesPathological examinationClinicopathological dataMicroinvasive carcinomaMammographic screeningClinical managementPathological diagnosisTreatment recommendationsBreast cancerDisease entityPubMed databaseMedical CollegeLiterature searchCarcinomaEarly detectionDiagnosisCumulative dataMicroinvasionMicroinvasive Carcinoma (T1mic) of the Breast
Prasad M, Osborne M, Giri D, Hoda S. Microinvasive Carcinoma (T1mic) of the Breast. The American Journal Of Surgical Pathology 2000, 24: 422-428. PMID: 10716157, DOI: 10.1097/00000478-200003000-00012.Peer-Reviewed Original ResearchConceptsDuct carcinomaMicroinvasive carcinomaPositive axillary lymphChest wall recurrenceFoci of invasionHigh-grade nucleiUnderwent lumpectomyAxillary lymphTNM criteriaClinicopathologic dataTubular carcinomaMean ageInvasive fociRadiation therapyAnticytokeratin antibodyEquivocal casesMammographic abnormalitiesPatientsRoutine examinationCarcinomaMuscle actinHistologic slidesMean numberOcular micrometerMICB
1999
Microinvasive carcinoma of the breast: can it be diagnosed reliably and is it clinically significant?
Hoda, Prasad, Moore, Hoda, Giri. Microinvasive carcinoma of the breast: can it be diagnosed reliably and is it clinically significant? Histopathology 1999, 35: 468-470. PMID: 10583563, DOI: 10.1046/j.1365-2559.1999.0820a.x.Commentaries, Editorials and LettersConceptsDefinition of microinvasionPresence of microinvasionSitu breast carcinomaUtility of immunohistochemistryMicroinvasive carcinomaHistological featuresReparative changesBreast carcinomaClinical significanceSitu carcinomaMicroinvasionCarcinomaFurther treatmentCommon problemImmunohistochemistryBreastDiagnosisDouble Immunolabeling with Cytokeratin and Smooth-Muscle Actin in Confirming Early Invasive Carcinoma of Breast
Prasad M, Hyjek E, Giri D, Ying L, O'Leary J, Hoda S. Double Immunolabeling with Cytokeratin and Smooth-Muscle Actin in Confirming Early Invasive Carcinoma of Breast. The American Journal Of Surgical Pathology 1999, 23: 176-181. PMID: 9989844, DOI: 10.1097/00000478-199902000-00006.Peer-Reviewed Original Research
1998
Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast.
Prasad M, Osborne M, Hoda S. Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast. Anatomic Pathology 1998, 3: 209-32. PMID: 10389587.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMicroinvasive carcinomaCell infiltrateNuclear gradeSitu carcinomaMalignant cellsMyoepithelial cellsVascular channel involvementInflammatory cell infiltrateFinal pathology reportStatus of marginsUniform diagnostic criteriaInvasive cellsBasement membraneNonneoplastic breast tissueDiagnostic uniformityExcellent prognosisRetrospective studyStromal changesExcised specimenHistologic assessmentPathology reportsHistopathologic diagnosisInvasive fociStromal alterationsTherapeutic decisions